uploads///Viread

How Gilead’s Viread, Complera, and Letairis Performed

By

Updated

Viread revenue trends

In 4Q17, Gilead Sciences’ (GILD) Viread generated revenues of $212 million compared to $324 million in 4Q16, which reflected a ~35% decline on year-over-year (or YoY) basis and a 23% decline quarter-over-quarter. In 4Q17, in the US, Europe, and other international markets, Viread reported revenues of $119 million, $36 million, and $57 million, respectively, compared to $171 million, $68 million, and $85 million in 4Q16.

Article continues below advertisement

In fiscal 2017, Viread generated revenues of $1.1 billion compared to $1.2 billion in 2016. In 2017, in the US, Europe, and other international markets, Viread generated revenues of $514 million, $238 million, and $294 million compared to $591 million, $302 million, and $293 million in 2016. In the Nucleoside Reverse Transcriptase Inhibitor (or NRTIs) class of drugs, Viread competes with Epivir, Retrovir, and Ziagen, all commercialized by Pfizer (PFE) and GlaxoSmithKline’s (GSK) joint venture, ViiV Healthcare.

Complera/Eviplera revenue trends

In 4Q17, Complera generated revenues of $222 million compared to $387 million in 4Q16. In 4Q17, in the US, Europe, and other international markets, Complera generated revenues of $91 million, $118 million, and $13 million, respectively, compared to $146 million, $135 million, and $16 million in 4Q16.

In fiscal 2017, Complera generated revenues of $966 million compared to $1.5 billion in 2016. In 2017, in the US, Europe, and other international markets, Complera generated revenues of $406 million, $503 million, and $57 million, respectively, compared to $821 million, $580 million, and $56 million in 2016.

Letairis revenue trends

In 4Q17, Letairis generated revenues of $233 million compared to $226 million in 4Q16, which reflected ~3% growth on a YoY basis and 9% growth quarter-over-quarter. In fiscal 2017, Letairis generated revenues of $887 million compared to $819 million in 2016.

In the pulmonary arterial hypertension drugs market, Letairis competes with Actelion Pharmaceuticals’ Tracleer. In November 2017, Johnson & Johnson (JNJ) acquired Actelion Pharmaceuticals.

Advertisement

More From Market Realist